Leonardo Lorente1, María M Martín2, Agustín F González-Rivero3, Antonia Pérez-Cejas4, Mónica Argueso5, Alina Perez6, Luis Ramos-Gómez7, Jordi Solé-Violán8, José Alberto Marcos Y Ramos9, Nazario Ojeda10, Alejandro Jiménez11. 1. Intensive Care Unit. Hospital Universitario de Canarias. Ofra, s/n. La Laguna 38320. Santa Cruz de Tenerife. Spain. 2. Intensive Care Unit. Hospital Universitario Nuestra Señora de Candelaria. Crta del Rosario s/n. Santa Cruz de Tenerife - 38010. Spain. 3. Laboratory Department. Hospital Universitario de Canarias. Ofra, s/n. La Laguna 38320. Santa Cruz de Tenerife. Spain. 4. Laboratory Department. Hospital Universitario de Canarias. Ofra, s/n. La Laguna 38320. Tenerife. Spain. 5. Intensive Care Unit. Complejo Hospitalario Universitario Insular. Plaza Dr. Pasteur s/n. Las Palmas de Gran Canaria - 35016. Spain. 6. Internal Intensive Care Unit. Hospital Universitario de Canarias. Ofra, s/n. La Laguna 38320. Santa Cruz de Tenerife. Spain. 7. Intensive Care Unit. Hospital General La Palma. Buenavista de Arriba s/n, Breña Alta, La Palma 38713. Spain. 8. Intensive Care Unit. Hospital Universitario Dr. Negrín. Barranco de la Ballena s/n. Las Palmas de Gran Canaria 35010. Spain. 9. Intensive Care Unit. Hospital Doctor José Molina Orosa. Ctra. Arrecife-Tinajo, km 1.300. Arrecife. Lanzarote 35550. Spain. 10. Department of Anesthesiology. Hospital Universitario Dr. Negrín. Barranco de la Ballena s/n. Las Palmas de Gran Canaria 35010. Spain. 11. Research Unit. Hospital Universitario de Canarias. Ofra, s/n. La Laguna 38320. Santa Cruz de Tenerife. Spain.
Abstract
BACKGROUND: Cell death by apoptosis is increased in septic patients. However, there are not data about circulating concentrations of sFas (proapoptotic protein of extrinsic pathway) and Bcl2 (antiapoptotic protein of intrinsic pathway) in COVID-19 patients. Thus, our objective study was to determine whether exists an association between serum concentrations of sFas and Bcl2 and COVID-19 patient mortality. METHODS: This observational and prospective study of COVID-19 patients was performed in eight Intensive Care Units (ICU) from Canary Islands (Spain). Serum levels of sFas and Bcl2 at ICU admission were determined. Mortality at 30 days was the end-point study. RESULTS: Surviving patients (n=42) compared to non-surviving (n=11) had lower APACHE-II (p<0.001), lower SOFA (p=0.004), lower serum sFas levels (p=0.001) and higher serum Bcl2 levels (p<0.001). Logistic regression showed an association between high serum sFas levels and mortality after controlling for APACHE-II (OR=1.004; 95% CI=1.101-1.007; p=0.01) or SOFA (OR=1.003; 95% CI=1.101-1.106; p=0.004), and between low serum Bcl2 levels and mortality after controlling for APACHE-II (OR=0.927; 95% CI=0.873-0.984; p=0.01) or SOFA (OR=0.949; 95% CI=0.913-0.987; p=0.01). CONCLUSIONS: Thus, to the best of our knowledge, this is the first study reporting blood levels of sFas and Bcl2 in COVID-19 patients and its association with mortality.
BACKGROUND: Cell death by apoptosis is increased in septic patients. However, there are not data about circulating concentrations of sFas (proapoptotic protein of extrinsic pathway) and Bcl2 (antiapoptotic protein of intrinsic pathway) in COVID-19patients. Thus, our objective study was to determine whether exists an association between serum concentrations of sFas and Bcl2 and COVID-19patientmortality. METHODS: This observational and prospective study of COVID-19patients was performed in eight Intensive Care Units (ICU) from Canary Islands (Spain). Serum levels of sFas and Bcl2 at ICU admission were determined. Mortality at 30 days was the end-point study. RESULTS: Surviving patients (n=42) compared to non-surviving (n=11) had lower APACHE-II (p<0.001), lower SOFA (p=0.004), lower serum sFas levels (p=0.001) and higher serum Bcl2 levels (p<0.001). Logistic regression showed an association between high serum sFas levels and mortality after controlling for APACHE-II (OR=1.004; 95% CI=1.101-1.007; p=0.01) or SOFA (OR=1.003; 95% CI=1.101-1.106; p=0.004), and between low serum Bcl2 levels and mortality after controlling for APACHE-II (OR=0.927; 95% CI=0.873-0.984; p=0.01) or SOFA (OR=0.949; 95% CI=0.913-0.987; p=0.01). CONCLUSIONS: Thus, to the best of our knowledge, this is the first study reporting blood levels of sFas and Bcl2 in COVID-19patients and its association with mortality.
Authors: Laura Bergantini; Miriana d'Alessandro; Paolo Cameli; Dalila Cavallaro; Sara Gangi; Behar Cekorja; Piersante Sestini; Elena Bargagli Journal: Cells Date: 2021-11-15 Impact factor: 6.600